secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002072
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune reports ~$466M cash, runway into 2H 2026; updates RP1/RP2 clinical data
--------------------------------------------------------------------------------

- Preliminary cash and equivalents of ~$466M as of Dec 31, 2023; funds operations into second half of 2026.
- Updated clinical data for RP1 and RP2 presented at 42nd J.P. Morgan Healthcare Conference.
- Cash estimate is unaudited, subject to completion of quarterly closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924002072/0001104659-24-002072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924002072/tm242298d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer